One broader angle: While these briefing materials center on the clinical data submitted for this specific BLA (full approval 50-64, accelerated PMC for 65 ), I see no place in the (public) agenda for explicit discussion or even cross-reference of how manufacturing controls (e.g., residual plasmid DNA/impurities from the in vitro transcription process) and platform characteristics like biodistribution/persistence compare to or build on prior mRNA authorizations.
Public discussions and some prior ACIP workgroups have raised these platform topics before. Greater transparency here would help address ongoing questions without over-relying on historical data alone or closed input.